Physician profile
Reena Garg
NPI 1457586299
$185,268.72
in general payments reported to CMS, 2019-2025
26 companies · $58K in 2025
The $58K reported for 2025 was more than what 99% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $10K · 2021: $20K · 2022: $19K · 2023: $36K · 2024: $23K · 2025: $58K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $48K · Consulting Fee: $35K · Travel and Lodging: $13K · Food and Beverage: $7,950 · Honoraria: $7,787 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $4,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $48,170.00 |
| Consulting Fee | $34,896.50 |
| Travel and Lodging | $13,427.25 |
| Food and Beverage | $7,950.32 |
| Honoraria | $7,786.79 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $4,200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $49,506.65 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $32,324.98 | 2022-2025 | Envista Mx60 Iol, Stellaris Elite, Trulign Iol |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $28,620.66 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $14,380.29 | 2019-2021 | |
| Sight Sciences, INC. | $13,659.18 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Glaukos Corporation | $13,559.99 | 2023-2025 | Travoprost Intraocular Implant - Idose, Idosetr, Idose |
| Alcon Vision LLC | $11,728.65 | 2022-2025 | Hydrus Microstent, Clareon, Rocklatan |
| New World Medical,INC. | $10,335.14 | 2023-2025 | Ahmed Glaucoma Valve, Kahook Dual Blade, Streamline |
| Allergan, INC. | $6,284.01 | 2020-2022 | |
| Rxsight INC | $3,288.21 | 2022-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Mallinckrodt Hospital Products INC. | $600.57 | 2023-2025 | Acthar |
| Sun Pharmaceutical Industries INC. | $215.15 | 2021-2025 | Cequa |
| Dompe US, INC. | $154.40 | 2024-2025 | Oxervate |
| Genentech USA, INC. | $126.88 | 2025 | Susvimo |
| Astellas Pharma US INC | $110.93 | 2024 | Izervay |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $110.25 | 2024-2025 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $63.83 | 2024-2025 | Xdemvy |
| Rayner Intraocular Lenses Limited | $29.44 | 2023 | Rayone Emv, Rayone Aspheric, Omidria |
| Alcon Research LLC | $29.17 | 2025 | Hydrus Microstent |
| Novartis Pharmaceuticals Corporation | $28.60 | 2019 | |
| Thea Pharma INC. | $23.83 | 2025 | Iyuzeh |
| Ocular Therapeutix, INC. | $21.47 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $20.02 | 2025 | Tecnis Simplicity, Veritas Vision System |
| Harrow Eye, LLC | $18.82 | 2025 | Vevye |
| Eyevance Pharmaceuticals LLC | $14.14 | 2019 | |
| Kala Pharmaceuticals, INC. | $13.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reena Garg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.